Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Total Debt (2017 - 2021)

Sunshine Biopharma (SBFM) has disclosed Total Debt for 5 consecutive years, with $1.9 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Total Debt rose 100.21% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Dec 2021, up 100.21%, and an annual FY2021 reading of $1.9 million, up 100.21% over the prior year.
  • Total Debt was $1.9 million for Q4 2021 at Sunshine Biopharma, down from $3.2 million in the prior quarter.
  • Across five years, Total Debt topped out at $3.2 million in Q3 2021 and bottomed at $27541.0 in Q3 2019.
  • Average Total Debt over 5 years is $950126.2, with a median of $353467.5 recorded in 2019.
  • Peak annual rise in Total Debt hit 3148.59% in 2021, while the deepest fall reached 100.21% in 2021.
  • Year by year, Total Debt stood at $79710.0 in 2017, then surged by 289.81% to $310718.0 in 2018, then tumbled by 91.14% to $27541.0 in 2019, then soared by 3345.79% to $949006.0 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • Business Quant data shows Total Debt for SBFM at $1.9 million in Q4 2021, $3.2 million in Q3 2021, and $2.1 million in Q2 2021.